August 8, 2019
August 7, 2019
Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)
July 19, 2019
Retrotope Announces Completion of Series C Preferred Financing and Addition of a Lead Investor on the Board of Directors
June 10, 2019
Oncternal Therapeutics Completes Reverse Merger with GTx, Inc.
May 31, 2019
selectION, Inc. Announces $4.1M Series A Investment
May 7, 2019
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
March 13, 2019
EMA Grants Orphan Medicinal Product Designation for Retrotope’s RT001 in the Treatment of Infantile Neuroaxonal Dystrophy (INAD), a PLA2G6 associated neurodegeneration (PLAN)
March 7, 2019
GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement
January 3, 2019
Immusoft Raises $20 Million In Series B Financing
December 13, 2018